What is Argent BioPharma Limited?
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally.
RGTLF · Verdict
Limited reward · elevated risk
RGTLF's standout is volatility; balance sheet and cash flow weigh on the picture.
Based on 88% data coverage
RGTLF · Verdict
Top decile vs peers
Current ratio 0.19
-1591% free-cash-flow margin
Rev -50.2% CAGR · earnings +2.1%
-3058% net margin · 0% ROE
Model-based scoring. For information only — not financial advice.
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 5.65M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.